These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 36041326)

  • 41. SARS-CoV-2 Omicron Variant Binds to Human Cells More Strongly than the Wild Type: Evidence from Molecular Dynamics Simulation.
    Nguyen HL; Thai NQ; Nguyen PH; Li MS
    J Phys Chem B; 2022 Jun; 126(25):4669-4678. PubMed ID: 35723978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.
    Greaney AJ; Starr TN; Barnes CO; Weisblum Y; Schmidt F; Caskey M; Gaebler C; Cho A; Agudelo M; Finkin S; Wang Z; Poston D; Muecksch F; Hatziioannou T; Bieniasz PD; Robbiani DF; Nussenzweig MC; Bjorkman PJ; Bloom JD
    Nat Commun; 2021 Jul; 12(1):4196. PubMed ID: 34234131
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization.
    Xiong D; Zhao X; Luo S; Cong Y; Zhang JZH; Duan L
    J Phys Chem Lett; 2022 Jul; 13(26):6064-6073. PubMed ID: 35758899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapidly identifying new coronavirus mutations of potential concern in the Omicron variant using an unsupervised learning strategy.
    Zhao LP; Lybrand TP; Gilbert PB; Payne TH; Pyo CW; Geraghty DE; Jerome KR
    Sci Rep; 2022 Nov; 12(1):19089. PubMed ID: 36352021
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
    Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
    Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations.
    Buratto D; Saxena A; Ji Q; Yang G; Pantano S; Zonta F
    Front Immunol; 2021; 12():730099. PubMed ID: 34858396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
    Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
    J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies.
    Alenquer M; Ferreira F; Lousa D; Valério M; Medina-Lopes M; Bergman ML; Gonçalves J; Demengeot J; Leite RB; Lilue J; Ning Z; Penha-Gonçalves C; Soares H; Soares CM; Amorim MJ
    PLoS Pathog; 2021 Aug; 17(8):e1009772. PubMed ID: 34352039
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Omicron Binding Mode: Contact Analysis and Dynamics of the Omicron Receptor-Binding Domain in Complex with ACE2.
    Fazekas Z; Menyhárd DK; Perczel A
    J Chem Inf Model; 2022 Aug; 62(16):3844-3853. PubMed ID: 35849759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Global Prevalence of Adaptive and Prolonged Infections' Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
    Lennerstrand J; Palanisamy N
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America.
    Quinonez E; Vahed M; Hashemi Shahraki A; Mirsaeidi M
    Viruses; 2021 May; 13(5):. PubMed ID: 34067890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron.
    Hu YF; Hu JC; Chu H; Yau T; Zhang BZ; Huang JD
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.
    Alkhatib M; Salpini R; Carioti L; Ambrosio FA; D'Anna S; Duca L; Costa G; Bellocchi MC; Piermatteo L; Artese A; Santoro MM; Alcaro S; Svicher V; Ceccherini-Silberstein F
    Microbiol Spectr; 2022 Apr; 10(2):e0273221. PubMed ID: 35352942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor.
    Sinha S; Tam B; Wang SM
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutational Effect of Some Major COVID-19 Variants on Binding of the S Protein to ACE2.
    Li Z; Zhang JZH
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. "Is Omicron mild"? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies.
    Rajpal VR; Sharma S; Kumar A; Chand S; Joshi L; Chandra A; Babbar S; Goel S; Raina SN; Shiran B
    J Med Virol; 2022 Aug; 94(8):3521-3539. PubMed ID: 35355267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comprehensive analysis of the mutational landscape of the newly emerging Omicron (B.1.1.529) variant and comparison of mutations with VOCs and VOIs.
    Chakraborty C; Bhattacharya M; Sharma AR; Dhama K; Agoramoorthy G
    Geroscience; 2022 Oct; 44(5):2393-2425. PubMed ID: 35989365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.